Identificador persistente para citar o vincular este elemento:
https://accedacris.ulpgc.es/jspui/handle/10553/156435
| Campo DC | Valor | idioma |
|---|---|---|
| dc.contributor.author | Lista, Maria Jose | en_US |
| dc.contributor.author | Winstone, Helena | en_US |
| dc.contributor.author | Wilson, Harry D. | en_US |
| dc.contributor.author | Dyer, Adam | en_US |
| dc.contributor.author | Pickering, Suzanne | en_US |
| dc.contributor.author | Galao, Rui Pedro | en_US |
| dc.contributor.author | De Lorenzo, Giuditta | en_US |
| dc.contributor.author | Cowton, Vanessa M. | en_US |
| dc.contributor.author | Furnon, Wilhelm | en_US |
| dc.contributor.author | Martel Suárez, Nicolás Alfonso | en_US |
| dc.contributor.author | Orton, Richard | en_US |
| dc.contributor.author | Palmarini, Massimo | en_US |
| dc.contributor.author | Patel, Arvind H. | en_US |
| dc.contributor.author | Snell, Luke | en_US |
| dc.contributor.author | Nebbia, Gaia | en_US |
| dc.contributor.author | Swanson, Chad | en_US |
| dc.contributor.author | Neil, Stuart J. D. | en_US |
| dc.contributor.editor | Schultz-Cherry, Stacey | - |
| dc.date.accessioned | 2026-01-29T14:48:24Z | - |
| dc.date.available | 2026-01-29T14:48:24Z | - |
| dc.date.issued | 2022 | en_US |
| dc.identifier.issn | 0022-538X | en_US |
| dc.identifier.uri | https://accedacris.ulpgc.es/jspui/handle/10553/156435 | - |
| dc.description.abstract | The appearance of new dominant variants of concern (VOC) of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) threatens the global response to the coronavirus disease 2019 (COVID-19) pandemic. Of these, the alpha variant (also known as B.1.1.7), which appeared initially in the United Kingdom, became the dominant variant in much of Europe and North America in the first half of 2021. The spike (S) glycoprotein of alpha acquired seven mutations and two deletions compared to the ancestral virus, including the P681H mutation adjacent to the polybasic cleavage site, which has been suggested to enhance S cleavage. Here, we show that the alpha spike protein confers a level of resistance to beta interferon (IFN-β) in human lung epithelial cells. This correlates with resistance to an entry restriction mediated by interferon-induced transmembrane protein 2 (IFITM2) and a pronounced infection enhancement by IFITM3. Furthermore, the P681H mutation is essential for resistance to IFN-β and context-dependent resistance to IFITMs in the alpha S. P681H reduces dependence on endosomal cathepsins, consistent with enhanced cell surface entry. However, reversion of H681 does not reduce cleaved spike incorporation into particles, indicating that it exerts its effect on entry and IFN-β downstream of furin cleavage. Overall, we suggest that, in addition to adaptive immune escape, mutations associated with VOC may well also confer a replication and/or transmission advantage through adaptation to resist innate immune mechanisms. | en_US |
| dc.language | eng | en_US |
| dc.relation.ispartof | Journal of Virology | en_US |
| dc.source | Journal of Virology [eISSN 0022-538X], v. 96(23) (Diciembre 2022) | en_US |
| dc.subject | 32 Ciencias médicas | en_US |
| dc.subject | 320505 Enfermedades infecciosas | en_US |
| dc.subject | 2420 Virología | en_US |
| dc.subject.other | IFITM | en_US |
| dc.subject.other | SARS-CoV-2 | en_US |
| dc.subject.other | Type 1 interferon | en_US |
| dc.subject.other | VOC | en_US |
| dc.subject.other | Furin cleavage site | en_US |
| dc.title | The P681H Mutation in the Spike Glycoprotein of the Alpha Variant of SARS-CoV-2 Escapes IFITM Restriction and Is Necessary for Type I Interferon Resistance | en_US |
| dc.type | info:eu-repo/semantics/Article | en_US |
| dc.type | Article | en_US |
| dc.identifier.doi | 10.1128/jvi.01250-22 | en_US |
| dc.identifier.issue | 23 | - |
| dc.relation.volume | 96 | en_US |
| dc.investigacion | Ciencias de la Salud | en_US |
| dc.type2 | Artículo | en_US |
| dc.description.numberofpages | 21 | en_US |
| dc.utils.revision | Sí | en_US |
| dc.contributor.wosstandard | Schultz-Cherry, Stacey | - |
| dc.contributor.wosstandard | Schultz-Cherry, Stacey | - |
| dc.contributor.wosstandard | Schultz-Cherry, Stacey | - |
| dc.contributor.wosstandard | Schultz-Cherry, Stacey | - |
| dc.contributor.wosstandard | Schultz-Cherry, Stacey | - |
| dc.contributor.wosstandard | Schultz-Cherry, Stacey | - |
| dc.contributor.wosstandard | Schultz-Cherry, Stacey | - |
| dc.contributor.wosstandard | Schultz-Cherry, Stacey | - |
| dc.date.coverdate | Diciembre 2022 | en_US |
| dc.identifier.ulpgc | Sí | en_US |
| dc.contributor.buulpgc | BU-MED | en_US |
| dc.description.sjr | 1,795 | |
| dc.description.jcr | 5,4 | |
| dc.description.sjrq | Q1 | |
| dc.description.jcrq | Q2 | |
| dc.description.scie | SCIE | |
| dc.description.miaricds | 11,0 | |
| item.fulltext | Con texto completo | - |
| item.grantfulltext | open | - |
| crisitem.author.dept | GIR IUIBS: Diabetes y endocrinología aplicada | - |
| crisitem.author.dept | IU de Investigaciones Biomédicas y Sanitarias | - |
| crisitem.author.dept | Departamento de Bioquímica y Biología Molecular, Fisiología, Genética e Inmunología | - |
| crisitem.author.orcid | 0000-0001-8429-8374 | - |
| crisitem.author.parentorg | IU de Investigaciones Biomédicas y Sanitarias | - |
| crisitem.author.fullName | Martel Suárez, Nicolás Alfonso | - |
| Colección: | Artículos | |
Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.